Janssen Launches the Global ‘Mosaico’ HIV Vaccine Efficacy Clinical Trial in Partnership with NIAID and Others

HIV Vaccine

The National Institutes of Health (NIH) and partners today announced plans to conduct a Phase 3 HIV vaccine efficacy trial at multiple clinical research sites in North America, South America and Europe. Called HPX3002/HVTN 706 or Mosaico, the study team will assess whether an investigational vaccine regimen designed to induce immune responses against a variety of global HIV strains can safely and effectively prevent HIV acquisition among men who have sex with men and transgender people. A complementary study in women, called HPX2008/HVTN 705 or Imbokodo that launched in 2017 in five southern African countries, is ongoing.

Mosaico is sponsored by Janssen Vaccines & Prevention, B.V., part of the Janssen Pharmaceutical companies of Johnson & Johnson, with funding support from the NIH’s National Institute of Allergy and Infectious Diseases (NIAID). The HIV Vaccine Trials Network (HVTN), headquartered at the Fred Hutchinson Cancer Research Center in Seattle, Washington, is facilitating the implementation of the study. Additional partners include the U.S. Army Medical Research and Development (USAMRDC).

The Phase 3 efficacy study will enroll 3,800 HIV-negative men and transgender people aged 18 to 60 years have sex with men and/or transgender people. It is anticipated to open for enrollment at clinical research sites in the United States later this year. Other sites will be in countries such as Argentina, Brazil, Italy, Mexico, Peru, Poland, and Spain.